Culture Expanded MSCs
Mesenchymal Stem Cells (MSCs) are the most commonly used cells in stem cell therapy and regenerative medicine, due to their high and multi-potency. Mesenchymal Stem Cells (MSCs) can be isolated from different tissues in the body.
In this article, you’ll be learning about culture-expanded MSCs, how MSCs can be expanded, The potency of MSCs and the type of cells they can differentiate into.
What are culture expanded Mesenchymal Stem cells?
Mesenchymal stem cells are high potent cells used for cellular therapy and isolated from different parts of the body. Mesenchymal stem cells can be used to improve the patient outcome in diseases and conditions such as autoimmune diseases, degenerative diseases, nerve damage, diabetes mellitus, bone problems etc.
For every patient, millions of mesenchymal stem cells are needed and the exact amount varies according to disease, route of administration, administration frequency, weight, and age of patient.
Mesenchymal stem cells are expanded in a culture media, on a large scale in order to obtain the required quantity of cells needed for cellular therapy.
Culture expanded MSCs: How does it work?
Expanding Mesenchymal stem cells in a media involves step by step process of isolation and expansion.
Mesenchymal Stem Cells Isolation
Mesenchymal stem cells can be isolated from different tissues in the human body such as adipose tissues, dental pulp, human bone marrow, umbilical cord tissue, umbilical cord blood, peripheral blood and synovium.
Mesenchymal stem cells are expanded in culture to increase their yield and amplify their desired functions and potency.
Although the population of Mesenchymal Stem Cells obtained will vary from donor to donor, here are some steps to follow:
· Acquire fresh tissue extracts in strictly aseptic conditions, to maintain purity.
· To remove any cell clusters, you have to filter the cell suspension with a 70-mm filter mesh
· Use a centrifuge to roll the cells for about 5 minutes at 500g
· Suspend the cells again the cells to measure the cell viability and yield using Trypan blue exclusion
· Use in T75 culture dishes to culture the cells in 10 mL of complete MSC medium at a density of 25 × 106 cells/mL. You can then go on to Incubate the plates at 37 °C with 5% CO2 in a humidified chamber without any interruption.
· When it’s past 3 h, remove the non-adherent cells that accumulate on the surface of the dish by changing the medium and replacing it with 10 mL fresh complete medium.
· After an additional 8 h of culture, add 10ml fresh complete medium as a replacement for the existing medium. You’ll have to repeat this step every 8 h for up to 72 h of initial culture.
· Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Expansion of Mesenchymal Stem Cells in a culture media
Culture expanded mesenchymal cells undergo various stages from the preparation of the culture plate, thawing of Mesenchymal stem cells, and the actual expansion of Mesenchymal stem cells.
The reason behind the cultural expansion of Mesenchymal stem cells is to get them to differentiate into other cell types such as osteoblast, adipocyte, and mesenchymal stromal cells.
In preparation, to expand MSCs in a culture media, you need a culture ware. You can get one plastic or glassware plate and coat it with a sufficient amount of 0.1% gelatin. Don’t forget to aspirate the gelatin solution from the coated plate or flask before you use it.
The next step involves the thawing of the Mesenchymal stem cells, and here are a few steps for you to follow:
After the recommended culture medium and coated culture ware is ready and on standby, remove the vial of Mesenchymal Stem Cells from liquid nitrogen and incubate in a 37C water bath and pay close attention to it, until all the cells are completely thawed. The extent of completely thawed frozen cells and how fast, are what determines the cell viability.
Once the cells have thawed completely, take steps to avoid contamination by disinfecting the walls with 70% ethanol, before you proceed to the next step.
Place the cells in a hood, and carefully transfer the cells to a sterile tube with a pipette (1 or 2ml pipette), Do this in such a way to prevent bubbles.
Then, add drops of Mesenchymal Stem cell expansion medium that have been pre-warmed to 37C to the tube containing the Mesenchymal stem cells.
Be careful to take your time when adding the medium to avoid osmotic shock which could lead to decreased viability.
Proceed to mix the suspension slowly by pipetting up and down two times while avoiding any bubbles.
Place the tube in a centrifuge and centrifuge the tube at 300 x g for 2-3 minutes to roll the cells, and you should not vortex the cells.
After this, then decant as much of the supernatant as possible. These steps are necessary to remove residual cryopreservative (DMSO).
Suspend the cells in a total volume of 10 mL of Mesenchymal Stem Cell Expansion Medium again or any alternative of choice, pre-warmed to 37 °C, containing freshly added 8 ng/mL FGF-2 (F0291).
The next step involves placing the cell suspension onto a 10-cm tissue culture plate or a T75 tissue culture flask.
Maintain the cells in a humidified incubator at 37 °C with 5% CO2.
The next day, exchange the medium with fresh Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2*. Replace with fresh medium containing FGF-2 every two to three days thereafter.
Isolate the cells when they are approximately 80% confluent, using Trypsin-EDTA and passaged further or frozen for later use.
Expansion of Mesenchymal Stem Cells
Once the cells are actively proliferating and have reached a confluence of approximately 80% (before 100%), you should subculture the cells.
Then remove the medium from the 10-cm tissue culture plate containing the confluent layer of human mesenchymal stem cells, carefully and apply 3-5 mL of Trypsin-EDTA Solution, before proceeding to incubate in a 37 °C incubator for 3-5 minutes.
Crosscheck the culture to see if all the cells are completely detached. Then, add 5 mL Mesenchymal Stem Cell Expansion Medium to the plate.
Swirl the plate mildly to mix the cell suspension. Transfer the separated/isolated cells to a 15 mL conical tube.
Centrifuge the tube at 300 x g for 3-5 minutes to pellet the cells.
Throw the supernatant away and apply 2 mL Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2 to the conical tube and completely suspend the cells again. Remember not to vortex the cells.
Then, use a hemocytometer to count the number of cells.
Plate the cells at a density of 5,000-6,000 cells per cm2 into the appropriate flasks, plates, or wells in a Mesenchymal Stem Cell Expansion Medium containing 8 ng/mL FGF-2.
Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Functions of Culture Expanded MSCs
Mesenchymal stem cells are required to be expanded in order for them to be used clinically for therapeutic purposes.
The culture expanded MSCs can be induced to differentiate into adipocytes, osteocytes, hepatocytes, chondrocytes, tenocytes and cardiomyocytes.
Because of its potential to differentiate into different kinds of cells in the body, it can be used to manage liver problems, heart problems, joint and bone problems etc.
Mesenchymal stem cells are also used in tissue regeneration and modulation of the immune system. They possess anti apoptotic, angiogenic, anti fibrotic, and anti-oxidative properties.
However, the quantity of MSCs isolated from body tissues is not enough for clinical and therapeutic applications.
This is why MSCs are expanded in culture to increase their yield for desired therapeutic effect.
- Published in Blog
Medical applications of exosomes
Medical applications of exosomes
Exosome therapy is gaining popularity in regenerative medicine. So what exactly are exosomes? Exosomes are particles that are released but cannot be replicated. They are intrical in how cells talk to each other. One cell will have a bunch of vesicles that leave and head to another cell to deliver a “message.” These vesicles contain information in the form of chemicals, cytokines to particles of messenger RNA.
Where are Exosomes found?
Exosomes are produced from stem cells and can be found in a variety of tissues.
How are they different from Stem Cells?
Exosomes are contained in stem cells. They are messenger cells that travel to communicate with other cells to produce the needed proteins to repair damaged areas. The use of exosomes does not require donor cells to be injected in the body. Exosomes can be extracted from mesenchymal stem cells (MSCs), sterilized and then injected into the body.
Stem cell therapy injects donor cells into a specific location. These stem cells grow and divide to repair the injured area and create healthier cells overtime. Exosomes are extracted from mesenchymal stem cells and like stem cells are injected into the injured area. Exosomes get to work at communicating with the patient’s own cells and enhance communication among the cells to generate the necessary and needed cells for healing.
What Exactly is Exosome Therapy ?
Exosome products are generally used for orthopedic injuries. Much like stem cell therapy, the exosomes would be injected into the injured site. This is generally an outpatient therapy that is relatively painless.
What does Exosome Therapy Treat? (Medical applications)
Exosome therapy is used for a variety of musculoskeletal injuries, chronic pain, degenerative diseases and genetic disorders. Aging and injuries suppress your cells ability to communicate with each other. The whole purpose of exosomes is to promote communication between cells to repair damaged tissues.
Exosomes are also used to help repair the skin from effects of aging. Overtime, the dermal layer of the skin is damaged because of fragmentation in the collagen, resulting in the signs of aging and hindering the ability to heal wounds. Exosomes have been found to help the body ramp up its collagen production. Exosomes also help inhibit inflammatory cytokines. This means exosomes can help with Atopic Dermatitis, a common skin disorder.
Exosomes can also help with lyme disease. Lyme disease is a very complex disease that compromises the immune system. This can lead to the disruption of cellular health and function. Oftentimes, lyme disease patients experience difficulty with inflammation which exosomes are also known to treat.
Are Exosomes Safer than Stem Cells
While both therapies have a low risk of complications, exosome therapy does not involve a surgical procedure for harvesting cells. Stem cells’ primary job is to grow and divide new and healthy cells from the donor cells. At times these cells may rapidly multiply resulting in a tumor. Exosomes do not multiply, rather they are responsible for improving the communication among cells.
If you want to become a specialist in stem cell therapies, exosomes and MSCs with us, check our next training dates here
- Published in Blog
Wharton’s Jelly – how does it work?
Wharton’s Jelly Treatment
Wharton’s Jelly is the substance that helps lubricate and support the umbilical cord. What makes Wharton’s Jelly so special is it contains high levels of mesenchymal stem cells. These special stem cells adapt to fit the cells needed to help regenerate damaged tissue and relieve pain naturally.
The mesenchymal stem cells that come from Wharton’s Jelly contain the most potent stem cells that are rich in regenerative properties. Wharton’s Jelly also contains a good amount of collagen, hyaluronic acid, and anti-inflammatory properties. This makes them quintessential in regenerative medicine.
Regenerative medicine refers to treatments and medicine that is naturally occuring, stem cell therapies being included. Mesenchymal stem cells are harvested from the Wharton Jelly found in the umbilical cord that has been donated by a healthy mother of a full term baby. These stem cells contain all the regenerative properties needed to help the body heal and relieve pain naturally.
How does this treatment work?
Mesenchymal stem cells are injected into the body and have the ability to transmute into cells that are needed to repair damaged tissue and relieve inflammation. These cells harness the potent regenerative properties that help rebuild the injured part of the body and provide long lasting natural pain relief. Unlike pain medicines which provide temporary relief that mask the symptoms and are harmful to the body if taken long term, the stem cells found in Wharton’s Jelly are naturally occurring and natural to the body.
What is Wharton’s Jelly best used for?
Wharton’s Jelly is best used in patients with degenerative diseases and musculoskeletal injuries. The anti-inflamatory and regenerative properties go to work at repairing damaged tissues. Repaired tissue means lasting pain relief and restored function.
What can someone expect?
Once a patient and doctor have decided on this type of stem cell treatment, patients can expect a relatively painless process. Stem cells are injected into the site and immediately go to work. Injections are virtually painless and there are no known negative side effects. Patients can generally get right back to the activities they love. Doctors will discuss treatment plans based on individual needs and in some cases resting an injured area for a particular period of time will be needed.
The mesenchymal stem cells found in Whorton’s Jelly have proven to be a very successful therapeutic method to treat a number of degenerative issues and injuries. This therapy is relatively painless, with no known negative side effects making it an excellent choice in treatment. Instead of masking the pain with dangerous medicine, stem cell therapy offers a naturally occurring solution that aims to repair the damaged tissue and resolve the problem.
If you want to learn more about Wharton’s Jelly Treatment and how can you help your patients, you can check our next training course here
- Published in Blog
How Exosomes Can Revolutionize Your Healthcare Practice
Cellgenic has worked closely with physicians all around the world for over a decade, and in working shoulder to shoulder with the rest of the medical community, we’ve gotten a feel for what we feel their main grievances are when incorporating regenerative medicine into their practice. We’ve found that primarily, the largest hurdles have been the large upfront costs, the long procedure times, and the difficulty procuring patients.
For a long time, most of the history of the nascent field of regenerative medicine, physicians would have to spend multiple thousands of dollars training themselves to use the procedures required to treat patients. In order to use this training, they would need to buy large, heavy, and expensive medical processing equipment in order to actually process the cellular samples. And after that, they would have to go through the trouble of procuring the enzymes and medical supplies needed to perform the procedure itself.
Every step of the process was mired with difficulty, and all of this was before even the patient acquisition process, which has the potential to completely make or break a practice. This is to not even mention the procedure itself, which can take anywhere from three to five hours of a physician being on their feet, and a patient being subdued under local anesthesia. The final result is an uncomfortable and drawn out procedure that regenerative medicine physicians have been working for years to optimize.
Cellgenic Exosomes is the company’s flagship product, which stands ready to revolutionize the practice of regenerative medicine as we know it today. Exosomes are extracellular vesicles which float freely within the blood, very much like platelets. But that is where the similarities end, because exosomes have been recently discovered to do far more than previously thought. Current science has identified them as one of the cornerstones of intercellular communication, as the enzymes that they secrete are responsible for cell-signalling, including calling healthy cells to begin the process of repairing damaged tissue. Because they consist of proteins, they are able to be administered without a risk of rejection from the patient, and they’re able to immediately get to work within the body, utilizing their growth factors and anti-scarring proteins to target inflammation and damaged tissue within the body.
Utilizing a potent combination of growth factors and anti-scarring proteins, they target inflammation and damage within the cells and tissues of the body and begin repairing it. The administration of Cellgenic Exosomes is simple. Every order arrives cryogenically-preserved under dry ice, and from there physicians can store them in the freezer for over one year. To administer, they simply need to be thawed out and injected into the patient, without the need for expensive and bulky equipment. All in all, this new process should not take more than forty-five minutes, and has lower upfront costs than the previous standard of care for regenerative medicine practitioners.
For more information, please visit https://cellgenic.com/, or contact info@stemcellsgroup.com
- Published in Blog
ISSCA Opening of Uccle, Belgium Center with GCell & Stem Cell Training
After several months of organizing and developing a location, the Global Stem Cells Group has finalized the construction of a laboratory and regenerative medicine research center in Uccle, Belgium.
This facility serves both as a regenerative medicine treatment and research center, but also as a plastic surgery clinic. In addition to this, one of the primary goals of the Center is to serve as a place for the fostering of knowledge and experience regarding the different products and equipment required for the application of cellular therapies. As part of the inaugural ceremony a group of physicians were trained in the setup and use of the various regenerative medicine protocols and application process of these cells into the patients.
This center is a push into Europe for the Global Stem Cells Group. As the science advances, newer and more advanced therapies and technologies are being developed and released into the market with each passing month.
With the European Union being one of the largest consumer markets in the world, the finalization of a brick-and-mortar location in Brussels, Belgium is one that will mean great things for the Global Stem Cells Group, and the presence and proliferation of regenerative medicine throughout Europe and the world.
“This was a wonderful opportunity that we could have. It goes to show that even during this pandemic, the medical community is one that is still going strong. We’re still rallying together to look for new breakthroughs, and come up with the most beneficial treatment options for patients,” Said Benito Novas, founder of the International Society for Stem Cell Applications, “In addition to this, it also provides an excellent platform for the distribution of regenerative medicine therapies and equipment, including the revolutionary new GCell Machine,”
Indeed, the inaugural training at the Stem Cell Center in Uccle, Belgium was one that covered both of the more traditional methods of stem cell isolation and application– adipose and bone-marrow derived autologous cells, but this training was also one of the first in which the company had the ability to demonstrate the novel GCell Machine. Using a precise system of blades and filters, it is able to process a stem cell sample from adipose tissue in less than half of the time that it would take a physician to do so through traditional means.
This allows the patient to be more comfortable throughout the shorter procedure, as less anesthesia is also required than when operating under traditional means. The GCell is a minimally invasive, portable machine that allows physicians to fully unlock the potential of regenerative medicine as a component in their practice. Using their global network of distributors and licensed vendors, Global Stem Cells Group is working fervently to ensure no interruption in the global availability of the most cutting-edge regenerative medicine products.
- Published in News
How Cellgenic MSCs Revolutionize Regenerative Medicine
Stem Cells are revolutionizing the field of regenerative medicine, due to their intelligence. Once administered into the patient, they are able to identify and target areas of disease and damage. Adimarket’s Mesenchymal Stem Cell Product excretes growth factors, cytokines, and proteins, which all play a key role in the regeneration of tissue. Their anti-inflammatory and immunomodulatory properties mean that it is difficult for them to be rejected by the body. Additionally, they increase blood flow to the vital organs which need it the most.
Many proprietors of MSC products will claim that it is not necessarily important to have a high ratio of viable cells. They claim that it does not matter how many cells are ‘not viable’, or dead, so long as there is a high enough number of viable cells– however, current research has shown that this is not the case. These dead cells are detectable by the immune system, and it is believed that they can create an inflammatory response within the body at the treatment area, which would lower the effectiveness of the regenerative medicine treatments.
This bending of the science is harmful to our industry, which is why knowledgeable purveyors put one thing above all else– consistency. Our cellular concentrations are the same throughout each batch, and we make sure that there is a high ratio of viable cells. All of our samples are independently verified by a third party laboratory, and have been selected for their phenotypic and genotypic profile, characterized for optimum growth and stability. When the proper care is taken, Mesenchymal Stem Cell products have been identified as having the highest output of growth factors and stem cell factors among the current standards of care– as well as properties of angiogenesis, immunomodulation, and the potential for endogenous repair.
Cellgenic has been working for over a decade, constantly reinventing itself and reinforcing the products that we offer with the latest advancements in the field of regenerative medicine. We take every painstaking measure possible to ensure that the cellular samples that our customers use to treat their patients are second to none– this includes the consistent concentrations of our sample, which are the same throughout ensuring that every patient gets the same treatment. We offer the product in 10 million or 30 million live total nucleated cells, where other fabricators would have the same number of total cells. We ensure that every single product that we send out has been tested for low amounts of annexin, which is a cellular protein which serves as a marker for cell death.
All our Mesenchymal Stem Cell products come in 1cc vials cryogenically preserved– they are shipped overnight within the United States, conveniently delivered to your door in the morning. For use, the product is passively thawed between the palms of your hands– and ready to use when your patients are. MSC 10 contains 10 million live cells and is recommended for a single joint, or a small area. However, the MSC pure pro has 30 million live cells,and can be used for larger applications, or for up to three joints in the same patient at the same time.
If you are interested in finding out more about Cellgenic MSCs, you can send an eMail to info@stemcellsgroup.com
- Published in News
Global Stem Cells Group Announces Training in Brussels, Belgium for April 9/10th
The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians that are collaborating to treat diseases and lessen human suffering through the advancement of the field of regenerative medicine has announced plans for a training in Brussels, Belgium on April 9/10th. This course is a long-awaited return to the country of Belgium after months of inactivity in the region brought about by the COVID-19 pandemic. During this time, research proceeded, and shocking discoveries were made that further thrust regenerative medicine into the world’s stage, and as a result the curriculum has been reinforced with the latest in IV therapy and exosome protocols.
This training will be one of the first of 2021, reaffirming the Global Stem Cells Group’s presence in Europe as a key player in the field of regenerative medicine. Members from both Global Stem Cells Group & the International Society for Stem Cell Application’s Brussels Chapter will be there to assist in expanding research for and the practice of regenerative medicine across Europe.
“It’s good to know that the Global pandemic has not been able to stop the progress of business,” Says Benito Novas, founder and CEO of the Global Stem Cells Group, “With reopening happening slowly, but surely, we hope that more and more physicians and clinics will take up the benefits of regenerative medicine.As we continue to train patients with the GCell Machine, ”
This training is intended to teach physicians the value and process behind incorporating regenerative medicine into their own clinical practice. This includes a theoretical portion that goes over basic regenerative medicine biology and its application, but also includes a Hands-On portion in which doctors, in a controlled environment and guided by a team of medical professionals, will have the opportunity to see procedures be performed just a few feet away, and then get the opportunity to try it for themselves.
The Belgium Stem Cell Center is one that is outfitted with the latest technology in regenerative medicine processing, which ensures any students that pass through it receive an education in extraction, isolation, and application of Platelet-Rich Plasma, Adipose, and Bone Marrow-Derived Mesenchymal Stem Cells.
This training will also teach physicians how to utilize the GCell Machine to perform regenerative medicine therapies. GCell is a tissue homogenization device that is revolutionizing the future of regenerative medicine. It is an extremely compact, all-in-one unit that can homogenize and isolate the stem cells from an adipose sample. GCell’s process of homogenizing with a system of precise blades and filtering ensures that the sample can be processed within an hour, with little input from the physician when the machine begins to do its work.
Once the process is over, the end result is a final product that can be administered to patients within an hour after the initial tissue extraction. This is a far cry from the previous, muti-hour long treatments that physicians have grown accustomed to, and the shortened timespan and simplicity of the procedure is something that both doctors and their patients will greatly appreciate.
If you are interested in enrolling in this upcoming event, or to learn more about the different training opportunities available, you can visit us at our training website.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in News
Global Stem Cells Group Announces Partnership with Bioscience Cell Factory
Just earlier this week, Global Stem Cells Group has signed a historic agreement with a company known as Bioscience Cell Factory– this Dubai-based healthcare company will allow GSCG to act as their representatives operating in both the Middle East and Latin America. Through the acquisition of proprietary branding rights Global Stem Cells Groups will become committed to promote the widespread use of cellular therapy treatments that utilize Mesenchymal Stem Cells (MSCs).
This partnership is groundbreaking in nature, and promises to lead to a wide proliferation of cellular therapies in both the Middle East and Latin America, two regions that are rapidly developing, with a constantly-advancing standard of medical care. Global Stem Cells Group will be clinically equipped with the highest standards and quality procedures as set forth by the Bioscience Cell Factory, resulting in nothing but the best treatment methods available for patients around the world.
“I’m extremely excited about this partnership,” Said Benito Novas, CEO of the Global Stem Cells Group, “Bioscience Cell Factory is one of the most professional and scientifically-focused teams that I’ve ever had the pleasure of working with– I am looking forward to the start of what will be an extremely beneficial professional relationship that will provide our global reach with the quality of Bioscience’s laboratory,”
Indeed, the two firms are also announcing plans to do research together into the nature of adult Mesenchymal Stem Cells, and the benefits that they hold for the medical field. Through the training of physicians and the handling of cell samples in their laboratory, there are high hopes for the advancement of the field of regenerative medicine research. As one of the representatives of the Bioscience Cell Factory abroad, Global Stem Cells Group will further its goal of being a global leader in the regenerative medicine field.
About Bioscience Cell Factory
Bioscience Clinic is a global healthcare company that is based in Dubai, committed to the running of a laboratory for the banking and use of all sorts of allogeneic and autologous cellular products. Through the proliferation of cellular therapies throughout the world, Bioscience Clinic hopes to advance treatment options for some debilitating diseases that current medical science has been largely unable to target the root causes of.
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in News
Global Stem Cells Group Announces Training in Cochabamba, Bolivia at the End of November
The Global Stem Cells Group, a multi-disciplinary community of scientists and physicians that are collaborating to treat diseases and lessen human suffering through the advancement of the field of regenerative medicine has announced that the construction of their Stem Cell Center in Cochabamba, Bolivia, has concluded. What’s more, the organization has announced that, in celebration of the facility’s completion, the Center’s inaugural training course will take place at the end of November.
The new facility located in Bolivia is the 35th Stem Cell Center in the world, strengthening the Global Stem Cells Group’s presence worldwide as they seek to expand research for and the
practice of regenerative medicine across the globe. Representatives from the Group and local physicians in the area will both see the impact of this new clinic, which will offer a permanent space within the country where experts in the field can train Bolivian physicians in the latest stem cell research.
“I am very excited for the opportunity to train more Bolivian physicians. We’ve been laying the groundwork for this Stem Cell Center for a very long time, and it feels almost like a dream to have to ready to unveil to the world by the end of November,” Said Benito Novas, founder and CEO of the Global Stem Cells Group, “To be able to have a permanent location in Cochabamba, and to have spots quickly filling up for this training– I think it speaks volumes to the future of regenerative medicine being a bright one,”
This inaugural training is intended to not only teach physicians the value of incorporating regenerative medicine into their own clinics, but to ensure that there is a vast store of all the necessary equipment and supplies that are required for the wide array of cellular therapies that are available for patients around the world– including a highly interactive study session that goes over the extraction, isolation, and application of PRP, Adipose, ad Bone Marrow Stem Cells.
The Center will also provide access to several texts detailing procedure processes and treatment options that are available for reference after the training is completed.
If you are interested in learning more about the Global Stem Cell Group’s Onsite Regenerative Medicine Training, or to book your seat, you can visit us at our training website
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
- Published in News
ISSCA Announces Speaker’s List for 7th Annual Symposium
The International Society for Stem Cells Applications has officially announced and published its list of speakers for its 7th Annual Regenerative Medicine Symposium. The seventh event of its kind, it is another effort from the iSSCA to bring together a network of regenerative medicine practitioners from all over the world. At previous events, hundreds of physicians came to share in their knowledge regarding cellular therapies and the patients whose lives they can change, and the aim of this year is no different– of course, as a reunion of medical professionals, several steps will be taken to ensure proper social distancing measures, as well as frequent opportunities for sanitation.
As with previous editions of the event, the topics discussed and speakers involved have been updated and edited in an effort to reflect the changing of time and the rapid evolution of the field of regenerative medicine. That is why this symposium will focus on Cellular Therapies During and After the Pandemic. Coronavirus has changed life as we know it, but the scientific and medical communities have not stopped researching. In fact, cellular therapies have been an invaluable asset in managing the largest pandemic in modern history, due to their implications in treating respiratory failure and managing some of the complications induced by exposure to COVID-19. This has resulted in accelerated pathways for regulatory approval and increased funding for new regenerative medicine-based clinical trials, which will all be discussed in greater depth at the event.
But the Regenerative Medicine Symposium also provides a valuable networking opportunity for physicians in the Latin American community. “Here, people interested in cellular therapy can find everything they need to get on the right path to helping people with regenerative medicine,” Said Benito Novas, VP of Public Relations, ISSCA, “If you’ve done some research yourself, or really have no idea where to start– this would be the place. We’ve got vendors, instructors, and interview panels with several distinguished researchers,”
About ISSCA
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine.
Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.
For more information, please visit us at www.issca.us or send an email to info@stemcellsgroup.com.
- Published in News